03.06.15
NxThera Inc. has added to its executive ranks, hiring Patrick W. Fabian as chief commercial officer.
In his new role, Fabian will lead the development and execution of NxThera’s sales, marketing, training and education, and customer service strategies as the company prepares to commercialize its Rezūm System in the United States to treat benign prostatic hyperplasia.
“We are very pleased to have Patrick Fabian join our leadership team as chief commercial officer. Patrick has a tremendous track record of successfully bringing disruptive medical device technologies to market. Pat’s experience and demonstrated ability to design, communicate and execute sales and marketing programs for minimally invasive, office-based procedures in the U.S. will be invaluable to our NxThera team, as well as our urology partners, and the patients they treat,” said Bob Paulson, president/CEO of NxThera.
Fabian joins NxThera from Sonitus Medical Inc., where he served as vice president of Sales and Marketing from 2011 through 2014. Prior to Sonitus, Fabian was senior vice president of Sales and Training for Acclarent Inc. until its acquisition by Ethicon Inc., a Johnson & Johnson company, in 2010. Previously, he held several executive positions at Accellent, and prior to Accellent, a variety of management and sales positions with Tyco, United States Surgical, and Pfizer.
Fabian received his B.A. in Business Administration from the University of St. Thomas.
In his new role, Fabian will lead the development and execution of NxThera’s sales, marketing, training and education, and customer service strategies as the company prepares to commercialize its Rezūm System in the United States to treat benign prostatic hyperplasia.
“We are very pleased to have Patrick Fabian join our leadership team as chief commercial officer. Patrick has a tremendous track record of successfully bringing disruptive medical device technologies to market. Pat’s experience and demonstrated ability to design, communicate and execute sales and marketing programs for minimally invasive, office-based procedures in the U.S. will be invaluable to our NxThera team, as well as our urology partners, and the patients they treat,” said Bob Paulson, president/CEO of NxThera.
Fabian joins NxThera from Sonitus Medical Inc., where he served as vice president of Sales and Marketing from 2011 through 2014. Prior to Sonitus, Fabian was senior vice president of Sales and Training for Acclarent Inc. until its acquisition by Ethicon Inc., a Johnson & Johnson company, in 2010. Previously, he held several executive positions at Accellent, and prior to Accellent, a variety of management and sales positions with Tyco, United States Surgical, and Pfizer.
Fabian received his B.A. in Business Administration from the University of St. Thomas.
NxThera is developing its Convective water vapor energy (Wave) technology platform to treat a variety of endourology conditions beginning with BPH, and including prostate cancer and kidney cancer. - See more at: http://www.mpo-mag.com/contents/view_breaking-news/2015-02-09/nxthera-hires-new-chief-development-and-operations-officer/#sthash.KVJXZBGC.dpuf
Based in Maple Grove, Minn., NxThera develops Convective water vapor energy (Wave) technology to treat various endourology conditions beginning with benign prostatic hyperplasia, and including both prostate and kidney cancers.